PUMA BIOTECHNOLOGY, INC. Net Change in Cash
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Net Change in Cash of $4.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $6.56M.
- PUMA BIOTECHNOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$6.19M.
- PUMA BIOTECHNOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$7.83M.
- PUMA BIOTECHNOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$14.81M.
- PUMA BIOTECHNOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$39.58M.
- PUMA BIOTECHNOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$15.37M, a 294.90% decline from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $7.88M, a 125.26% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $3.50M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.81M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $6.56M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$39.58M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$15.69M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$14.56M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$6.19M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$15.37M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$17.32M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$17.44M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$7.83M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $7.88M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $5.60M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$16.19M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | -$14.81M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $3.50M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $5.26M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$19.95M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$8.07M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$22.16M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$21.35M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $4.55M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $10.36M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $24.24M 10-K · filed 2023-03-02 | |||
| 2020-09-30 | $29.03M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $29.85M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $22.84M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$39.53M 10-K · filed 2022-03-03 | |||
| 2019-09-30 | -$40.66M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$72.40M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$59.63M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $26.72M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$13.40M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $14.21M 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | -$3.15M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | -$112.80M 10-K · filed 2020-02-28 | |||
| 2017-09-30 | -$114.78M 10-Q · filed 2018-11-05 | |||
| 2017-06-30 | -$113.68M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $162.93M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |